About Modern Diagnostic and Research Centre Ltd IPO

Incorporated in 1985, Modern Diagnostic & Research Centre Limited (MDRC) is a diagnostic chain in India, offering a comprehensive range of pathology and radiology services.

The company provides reliable diagnostic tests, home specimen collection, online reports, and customized test packages for institutional customers and patients based on their specific needs.

The company operates 21 centers (18 labs, 3 diagnostic centers) across 8 states, offering diagnostic services like ultrasound, CT, MRI, X-ray, ECG, PFT, and specialized labs for heart and neuro care.

Services:

  • Pathology:MDRC provides a wide array of tests, including high-end molecular diagnostics, cytogenetics, and specialized panels for genetic disorders and cancer.
  • Radiology:The centre offers advanced imaging services such as MRI, CT scans, ultrasound, and digital X-rays, utilizing state-of-the-art equipment like a 3-Tesla MRI machine and a 128-slice CT scanner.
  • Home Sample Collection:MDRC offers home blood sample collection services in several cities, providing convenience for patients unable to visit the centre.

Competitive Strengths:

  • Experienced Promoter and Management Team
  • Comprehensive diagnostics provider delivering all-in-one solution at cost-effective prices
  • Focus on quality and customer service
  • Centralized information technology platform

Modern Diagnostic and Research Centre IPO Subscription Breakdown

Investory CategorySubscription PercentageAmount Raised (₹ Crores)
Qualified Institutional Buyers (QIBs)50%2049600 crores
Non-Institutional Investors (NIIs15%614880 crores
Retail Individual Investors (RIIs)35%1434720 crores

Modern Diagnostic and Research Centre IPO Financial Highlights

Modern Diagnostic and Research Centre Ltd’s total income 0 by 0.00% and total expenses 0 by 0.00%, resulting in an EBITDA 0 by 0.00% and a profit after tax (PAT) 0 by 0.00% between March 31, 2025 and March 31, 2026.

No Data Found
No Data Found

Modern Diagnostic and Research Centre IPO Strengths & Weaknesses

No Data Found
No Data Found

Modern Diagnostic and Research Centre IPO Important Dates & Issue Details

Allotment DateListing Date
05 Jan '2607 Jan '26

Modern Diagnostic and Research Centre IPO Lot Size and Investment Details

Minimum Lot Size--
Maximum Lot Size (Retail)--

The lot size of Modern Diagnostic and Research Centre Ltd ipo has been designed to ensure broad participation while maintaining optimal price discovery.

How to Apply for Modern Diagnostic and Research Centre IPO

  1. Log in to your Choice account
  2. Select IPO
  3. Enter the number of lots and your price
  4. Verify UPI ID
  5. Complete the transaction on your UPI app

Contact & Registrar Details

Contact Details

Address

Address

Phone Number

Phone Number

+91

Email

Email

Website

Website

Registrar Details

Address

Registrar Name

Phone Number

Phone Number

+91

Email

Email

Website

Website

Modern Diagnostic and Research Centre IPO FAQs

The minimum lot size is 1600 shares with a price band of ₹85 to ₹90 per share, requiring a minimum investment of ₹2,88,000.

Check allotment status on the registrar's website using PAN number or application number after the Modern Diagnostic and Research Centre Ltd ipo allotment date.

The listing date of Modern Diagnostic and Research Centre Ltd ipo is scheduled for 07 Jan '26 on NSE/BSE .

Investment decisions should be based on your risk appetite, financial goals, and a thorough analysis of the company's fundamentals and growth prospects.

Consider factors like company fundamentals, valuation, market conditions, and your investment portfolio before making any investment decision.

You can Modern Diagnostic and Research Centre Ltd ipo apply online through your broker's trading platform, mobile app, or through the ASBA facility via internet banking.

The Modern Diagnostic and Research Centre Ltd ipo allotment date and listing date are 05 Jan '26and 07 Jan '26, respectively.

Yes, you can apply through your bank's internet banking portal. The funds will remain in your account until allotment, and no need for separate IPO funding.